Integer (ITGR Quick QuoteITGR - Free Report) reported $464.11 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 2.6%. EPS of $1.60 for the same period compares to $1.55 a year ago.

The reported revenue represents a surprise of +2.58% over the Zacks Consensus Estimate of $452.46 million. With the consensus EPS estimate being $1.38, the EPS surprise was +15.94%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Integer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Sales- Medical Sales- Other Markets: $10.09 million versus $9.91 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -42.8% change.
• Sales- Medical Sales- Cardio & Vascular: $280.31 million versus the four-analyst average estimate of $275.13 million. The reported number represents a year-over-year change of -2.3%.
• Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation: $173.71 million versus the four-analyst average estimate of $169.27 million. The reported number represents a year-over-year change of +1%.

View all Key Company Metrics for Integer here>>>

Shares of Integer have returned +27.4% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.